17:57 , Aug 29, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Antibody scaffolds Sialylation of immune complexes could enhance the response to HIV vaccines. Patients who spontaneously controlled HIV without therapy and patients who had evolved neutralizing activity against a panel of 11 HIV-1 viruses...
15:54 , Aug 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious

INDICATION: HIV/AIDS Primate studies suggest combining CD4 mimetics with HIV gp120-based vaccines could help prevent HIV. In macaques challenged with simian human immunodeficiency virus (SHIV) immunized with HIV gp120 variants, a CD4 mimetic prevented infection...
18:19 , May 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: HIV/AIDS Patient sample and cell culture studies identified three broadly neutralizing antibodies (bNAbs) against HIV gp120 that could help treat the infection. Screening of neutralizing antibodies against HIV gp120 isolated from a patient with...
18:33 , Apr 3, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: HIV / AIDS Patient sample and cell culture studies identified a neutralizing antibody against HIV gp120 that could help treat HIV/AIDS. Screening of peripheral blood B cells from a patient followed by testing of...
04:48 , Nov 3, 2017 |  BC Week In Review  |  Clinical News

ViiV's HIV candidate fostemsavir meets in Phase III

ViiV Healthcare Ltd. (Brentford, U.K.) said oral fostemsavir (GSK3684934) (formerly BMS-663068) met the primary endpoint in the Phase III BRIGHTE trial to treat heavily treatment-experienced patients with HIV-1 infection. In the trial's randomized cohort, fostemsavir...
23:27 , Oct 27, 2017 |  BC Extra  |  Clinical News

ViiV's HIV candidate meets in Phase III

ViiV Healthcare Ltd. (Brentford, U.K.) said oral fostemsavir (GSK3684934) met the primary endpoint in the Phase III BRIGHTE trial to treat heavily treatment-experienced patients with HIV-1 infection. In the trial's randomized cohort, fostemsavir led to...
00:01 , Sep 21, 2017 |  BC Extra  |  Preclinical News

NIAID, Sanofi develop trispecific bNAb for HIV

In a paper published in...
20:43 , Jul 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: HIV / AIDS Macaque studies suggest adding a boost containing five HIV gp120 variants to HIV vaccine regimens could help prevent infection by the virus. The boost consists of the adjuvant GLA-SE and five...
01:05 , Feb 16, 2017 |  BC Innovations  |  Translation in Brief

WinSanTor, with feeling

The founders of WinSanTor Inc. have discovered that the muscarinic antagonist pirenzepine can stimulate peripheral nerve growth and function and treat a preclinical model of diabetic neuropathy as a topical agent. The company has started...
14:12 , Nov 30, 2016 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: HIV/AIDS Patient sample and cell culture studies identified a broadly neutralizing antibody (bnAb) against HIV gp120 that could help treat HIV infection. Screening of peripheral blood memory B cells from a patient with broad-spectrum...